plasminogen activator (tisokinase / tisokinase, Kowa / Hapase)
✓ ApprovedAsahi Kasei · 治疗药物
什么是 plasminogen activator?
plasminogen activator 是一种治疗药物,由Asahi Kasei研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。
药物档案
| 商品名 | tisokinase, tisokinase, Kowa, Hapase |
| 公司 | Asahi Kasei |
| 给药途径 | Injectable (Others), Intravenous (IV) |
| 状态 | Approved |
治疗适应症
plasminogen activator 针对 1 个适应症,涉及 1 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Cardiac disorders | Myocardial infarction | ✓ Approved |
相关研究文献
Comprehensive analysis of transient elastography, ultrasonography, and blood biomarkers in SOS diagnosis and prediction.
Harada Naonori N, Okamura Hiroshi H, Koh Hideo H, Abo Koji K et al.
Sinusoidal obstruction syndrome (SOS) is a potentially fatal complication following allogeneic hematopoietic cell transplantation (allo-HCT). The Seattle and Baltimore criteria are widely used for diagnosing SOS, but both have limitations in terms of sensitivity and positive predictive value. While liver biopsy provides definitive evidence, it carries a high risk of hemorrhage, prompting the need for less invasive diagnostic methods. Recently, non-invasive tests, including abdominal ultrasound (AUS) and liver stiffness measurement using transient elastography (TE), and several blood biomarkers such as procollagen III peptide (P3P) and plasminogen activator inhibitor 1 (PAI-1) have been reported for the diagnosis and prediction of SOS, though their applicability in different settings remains unclear due to insufficient validation. To date, there are no studies comparing the diagnostic utility of AUS, TE, and blood biomarkers in a single cohort of allo-HCT patients. Further research is needed to refine diagnostic approaches and improve patient outcomes. The aim of this prospective study was to comprehensively and quantitatively evaluate the diagnostic and predictive utility of these markers for SOS, using a stringent definition of SOS primarily based on histopathological confirmation through liver biopsy or autopsy. In a prospective study of 180 patients undergoing allo-HCT, we evaluated the diagnostic and predictive utility of liver stiffness measured by transient elastography (TE), abdominal ultrasound, and various blood biomarkers. Univariable logistic regression and area under the receiver operating characteristics curve (AUC) analyses were used to assess the significance of these measures. Out of 180 patients, 10 developed definitive SOS, most of which were based on pathological diagnosis. In the 48 patients who developed post-transplant liver injury, the AUC analysis highlighted that PAI-1 and liver stiffness were especially significant diagnostic markers for SOS, with highest AUCs of 0.85 (95% CI: 0.67-1.00) and 0.83 (95% CI: 0.67-0.98), respectively. Combining these markers resulted in an excellent diagnostic AUC of 0.96 (95% CI: 0.88-1.00). For predicting SOS in the 180 patients, pre-transplant P3P and liver stiffness were especially significant, with the highest AUCs of 0.82 (95% CI: 0.67-0.97) and 0.80 (95% CI: 0.61-0.99), respectively. Kinetic analysis showed that liver stiffness, PAI-1, and P3P levels increased throughout the early period after allo-HCT only in patients who developed SOS. Liver stiffness, PAI-1, and P3P are valuable markers for diagnosing and predicting SOS after allo-HCT. The combination of them offers excellent diagnostic and predictive accuracy, suggesting these markers should be integrated into clinical practice for better management of SOS in allo-HCT patients.
Autophagy activator AA-20 engages CDK5 to promote lipophagy and improve neurodegeneration-associated phenotypes.
Tan Ee Phie EP, Ambaye Lydia L, Mahul-Mellier Anne-Laure AL, Zhang Yuting Y et al.
Lipophagy, the selective degradation of lipid droplets (LDs) by autophagy, has the potential to ameliorate neurodegenerative diseases such as Parkinson's (PD) and Alzheimer's (AD), wherein LD accumulation has been linked to the exacerbation of the proteinopathy component of neurodegeneration. Pharmacological lipophagy inducers remain scarce. We previously identified AA-20 as a novel autophagy activator that acts independently of mTORC1 inhibition, thereby providing a means of stimulating autophagy while avoiding the immunosuppressive side effects associated with direct mTORC1 inhibition. Prior work also showed that AA-20 treatment reduces PolyQ aggregate levels in several C. elegans tissues. Here, we demonstrate that AA-20 enhances LD recruitment to autophagosomes and promotes LD degradation via lysosomal acid lipase activation in murine hippocampal neuronal cells, consistent with lipophagy activation. In human Swedish Amyloid Precursor Protein mutated cerebral organoids, two weeks of AA-20 treatment normalized aberrant lipidomic profiles by selectively reducing various disease-associated lipids, while also correcting the AD-associated electrical hyperexcitability phenotype. Moreover, we identified cyclin-dependent kinase 5 (CDK5), a neuronal kinase linked to AD hyperexcitability and PD pathology, as a target of AA-20. AA-20-induced autophagy and lipid clearance in HT22 cells require CDK5. In a neuronal seeding model of α-synuclein pathology, AA-20 reduced pS129-α-synuclein levels. Collectively, these findings indicate AA-20 can promote lipophagic clearance of LDs and mitigate multiple cellular phenotypes associated with lipidopathy and proteinopathy in neurodegenerative disease models. Neurodegenerative diseases such as Alzheimer's and Parkinson's are associated with impaired autophagy and abnormal lipid droplet (LD) accumulation. Few small molecules enhance neuronal lipid clearance without inhibiting mTORC1, but chronic blockade of which is associated with immunosuppressive and metabolic side effects. This study shows that AA-20, an mTORC1-independent autophagy activator, promotes lipophagic LD clearance in neuronal cells and reduces selected disease-associated lipids in human Alzheimer's cerebral organoids in a lysosomal acid lipase-dependent manner. AA-20 binds CDK5 and appears to modulate, rather than classically inhibit, this neuron-enriched kinase. In an exploratory Parkinson's neuron model, AA-20 also reduced pathological α-synuclein phosphorylation. These findings support further investigation of AA-20 as a tool to probe neuronal lipid clearance and neurodegeneration-associated phenotypes.
Synthetic reaction-diffusion patterning in mammalian cells.
Wang Sheng S, Du Rongrong R, Linton James M JM, Elowitz Michael B MB
During development, periodic patterns arise through reaction-diffusion (RD) circuits involving local activation and long-range inhibition (LALI). Natural systems are complex, typically entangling regulation and transport in the same morphogens. It remains unclear what minimal circuits are sufficient for LALI patterning in mammalian cells, and whether they can be implemented in a modular fashion, allowing independent control of regulation and transport. Here, we designed synthetic LALI circuits using three natural and synthetic signaling systems-BMP, Activin, and the SNIPR pathway-and showed that they generate spatial patterns with distinct characteristic spatial scales. Model-guided design allowed flexible morphogen reassignment, with BMP4 acting as either short-range activator or long-range inhibitor. Gene expression noise degraded long-range order but preserved the dominant local spatial scale. Together, these results provide a modular, extensible synthetic framework for engineered patterning in mammalian cells.
A three-factor model can explain symmetry breaking and the n-1 rule during X-chromosome inactivation.
Guan Kaiyun K, Liu Jerry M JM, Calabrese J Mauro JM, Elston Timothy C TC
X-chromosome inactivation (XCI) is a mammalian gene regulatory process that via chromosome-scale transcriptional silencing, leaves active a single X chromosome per diploid genome complement. The mechanisms that enable cells to select the appropriate number of X chromosomes to inactivate while leaving others active remain unclear. We demonstrate that all known chromosomal counting scenarios during XCI can be accounted for by a three-factor mathematical model that includes (1) Xist , the long noncoding RNA (lncRNA) responsible for gene silencing during XCI in eutherians, (2) an X-linked transcriptional activator of Xist , and (3) the autosomally-encoded SPEN, an Xist RNA-binding protein that is essential for gene silencing during XCI. In our model, symmetry between active X chromosomes is broken by stochastic differences in the number of Xist molecules that associate with the X chromosomes at the onset of XCI. Subsequently, integrated positive and negative feedback loops amplify then propagate superstoichiometric assemblies of SPEN complexed with Xist on the inactive chromosome(s), and select for levels of X-linked activator that enable only one X chromosome per diploid genome complement to remain active. Thus, asymmetric propagation of the SPEN- Xist ribonucleoprotein complex may play an essential role in symmetry breaking and chromosomal counting during XCI, independently of or in concert with cis-acting networks of DNA regulatory elements. Our results also have conceptual implications for gene regulatory circuits on autosomes. X-chromosome Inactivation (XCI) is a mammalian gene regulatory process in which one of two X chromosomes in each female cell is randomly selected for silencing. How cells select only one X for silencing is not understood. We use mathematical modeling to demonstrate that a mechanism in which positive feedback amplifies fluctuations in molecular abundances is sufficient to explain XCI. In particular, the X-linked noncoding RNA Xist and the RNA-binding protein SPEN form a positive feedback loop that propagates a ribonucleoprotein complex along the X chromosomes in all-or-none fashion. Our model demonstrates how the asymmetric propagation of an RNA-protein effector complex might establish monoallelic gene expression during XCI. Analogous RNA-driven regulatory circuits may underlie other instances of monoallelic gene expression.
Gene regulatory logic underlying the differentiation of mixed lineages in human thymic epithelial cells.
Prabakar Rishvanth K RK, Chapin Sarah R SR, Lin Yong Y, Staklinski Stephen J SJ et al.
The thymus enacts central tolerance through thymic epithelial cells (TECs), which present self-antigens to developing T cells to remove self-reactive cells, preventing autoimmunity. Human TECs include populations that express lineage-committed programs corresponding to distinct peripheral tissues, yet how they acquire these programs and whether these TEC subpopulations are genetically related and conserved in mice remain unknown. Using matched single-cell gene-expression and chromatin-accessibility profiling of 126,687 human TECs, we identified 17 TEC subsets defined by their distinct expression profiles of 1,843 cell type restricted-antigens (CRAs) from 48 peripheral cell types. With a new phylogenetic reconstruction method, we show that lineage-committed TECs share a common ancestor, retain a thymus-specific mixed identity through co-expression of multiple CRA signatures, and are specified by coordinated activator and repressor regulons. We also identified a basement-membrane-collagen-rich state (BMC-TECs) with progenitor-like properties. Finally, mouse TECs shared the regulatory strategy but conserved few master transcription-factor drivers. This study mechanistically characterizes human TEC subpopulations and reveals the gene regulatory logic that leads to their distinct diversification and mixed identities in humans and mice.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →